Peripheral‐type benzodiazepine receptors in anxiety disorders

Acta Psychiatrica Scandinavica

Volumn 84, Issue 6, 1991, Pages 537-544

  Rocca, P ^a,b   Ferrero, P ^a   Gualerzi, A ^a   Zanalda, E ^a   Maina, G ^a   Bergamasco, B ^a   Ravizza, L ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Department of Neurosciences   (Italy)

Author keywords

anxiety disorder; benzodiazepine; lymphocyte; receptor

Indexed keywords

ATROPINE; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR; DELORAZEPAM; DIAZEPAM; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; SCOPOLAMINE METHYL BROMIDE;

ADULT; AGE; ANXIETY; ARTICLE; BINDING SITE; CONTROLLED STUDY; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; OBSESSION; PANIC;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; HUMAN; ISOQUINOLINES; LONG-TERM CARE; LYMPHOCYTES; N-METHYLSCOPOLAMINE; OBSESSIVE-COMPULSIVE DISORDER; PARASYMPATHOLYTICS; RADIOLIGAND ASSAY; RECEPTORS, GABA-A; RECEPTORS, MUSCARINIC; SCOPOLAMINE DERIVATIVES;

EID: 0026316060     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1991.tb03190.x     Document Type: Article

References (57)

1. Imipramine and chlordiazepoxide in depressive and anxiety disorders
2. Buspirone and diazepam in the treatment of anxiety: a controlled study
3. Diazepam, propranolol and their combination in the management of chronic anxiety
4. Long‐term treatment of anxiety and risk of withdrawal
5. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial I. Efficacy in short‐term treatment.
6. Tricyclic antidepressant and monoamine oxidase inhibitors in the treatment of agoraphobia
7. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms
8. Drug treatment of obsessive‐compulsive disorder
9. Importance of a novel GABAa receptor subunit for benzodiazepine pharmacology
10. Benzodiazepine receptor‐mediated experimental “anxiety” in primates.
11. Severe anxiety induced by FG 7142, a β‐carboline ligand for benzodiazepine receptors
12. A benzodiazepine receptor‐mediated model of anxiety: studies in nonhuman primates and clinical applications
13. Benzodiazepine receptors on human blood platelets
14. Imaging of C11 labeled RO15–1788 binding to benzodiazepine receptors in human brain by positron emission tomography
15. Peripheral benzodiazepine binding sites
16. Molecular mechanism of peripheral benzodiazepine receptors
17. Mitochondrial benzodiazepine receptors regulate steroid biosynthesis
18. The peripheral‐type benzodiazepine receptor is functionally linked to Leydig cell steroidogenesis
19. Peripheral‐type benzodiazepine receptors are involved in the regulation of cholesterol side chain cleavage in adrenocortical mitochondria
20. 3H)‐Ro 5‐4864 in rat brain and kidney.
21. Benzodiazepine binding sites in mice forebrain and kidneys: evidence for similar regulation by GABA receptor agonists
22. Chronic phenobarbital administration affects GABA and benzodiazepine receptors in the brain and periphery
23. Opposite effects of an agonist Ro 5‐4864 and an antagonist PK 11195 of the peripheral type benzodiazepine binding sites on audiogenic seizure in DBA 2J mice
24. Opposite effects of two ligands for peripheral type benzodiazepine binding sites
25. Isolation and characterization of a triakontetraneuropeptide (TTN) derived from DBI, with specification at the Ro5‐4864 preferring benzodiazepine recognition sites
26. Inescapable shock reduces (3H)‐Ro 5‐4864 binding to “peripheral‐type” benzodiazepine receptors in the rat.
27. Increase in central and peripheral benzodiazepine receptors following surgery
28. Examination stress, platelet peripheral benzodiazepine binding sites, and plasma hormone levels
29. Central‐ and peripheral‐type benzodiazepine receptors
30. Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients
31. Decreased density of benzodiazepine receptors in lymphocytes of anxious patients: reversal after chronic diazepam treatment
32. The Yale‐Brown Obsessive Compulsive Scale I. Development, use and reliability.
33. The Yale‐Brown Obsessive Compulsive Scale II. Validity.
34. The assessment of anxiety states by rating
35. A rating scale for depression
36. Disturbo ossessivo‐compulsivo: possibilità di differenziazioni sulla base di evidenze cliniche.
37. Clinical diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
38. Mini Mental State
39. Parkinsonism: onset, progression and mortality
40. Isolation of mononuclear cells and granulocytes from blood
41. (3H)‐N‐Methylscopolamine binding to muscarinic receptors in human peripheral blood lymphocytes: characterization, localization on T lymphocyte subsets and age‐dependent change
42. Protein measurement with the Folin phenol reagent
43. 3H‐PK 11195 binding to “peripheral‐type” benzodiazepine receptors on human lymphocytes. Evidence of decrease binding in hepatic encephalopathy.
44. The diagnostic validity of anxiety disorders and their relationship to depressive illness
45. Panic disorder and major depression: biological relationships
46. Major depression and panic disorder: diagnostic and neurobiological relationship
47. Anxiety reconceptualized.
48. Delineation of two drug‐responsive anxiety syndromes
49. Clincial characteristics and family history in DSM‐III obsessive‐compulsive disorder
50. Neuronal‐glial differential processing of DBI to yield ligands to central or peripheral benzodiazepine recognition sites.
51. Protracted treatment with diazepam increases the turnover of putative endogenous ligand for the benzodiazepine/beta‐carboline recognition site
52. Cerebrospinal fluid content of diazepam binding inhibitor in chronic hepatic encephalopathy
53. Diazepam binding inhibitor like immunoreactivity (DBI‐LI) in human CSF: correlation with neurological disorders
54. In vivo treatment with benzodiazepine inhibit murine phagocyte oxidative metabolism and production of interleukin 1, tumor necrosis factor and interleukin‐6.